KEY FEATURES
| Full Name | Vascular Endothelial Growth Factor A |
|---|---|
| Synonym | VEGF; VEGF-A; VPF; Vascular Endothelial Cell Growth Factor A; Vascular Permeability Factor |
| Assay Type | Sandwich |
| Reactivity | Rat |
| Range | 15.6-1000pg/mL |
| Sensitivity | 6.3pg/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Rat VEGFA in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Rat VEGFA. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Rat VEGFA and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Rat VEGFA, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Rat VEGFA. You can calculate the concentration of Rat VEGFA in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Rat VEGFA ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (pg/mL) | 52.82 | 152.12 | 348.7 | 56.33 | 164.1 | 319.37 |
| Standard deviation | 3.34 | 8.84 | 13.32 | 3.42 | 7.14 | 14.02 |
| CV(%) | 6.32 | 5.81 | 3.82 | 6.08 | 4.35 | 4.39 |
RECOVERY
The recovery of Rat VEGFA spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 85-98 | 92 |
| EDTA plasma (n=8) | 85-96 | 90 |
| Cell culture media (n=8) | 90-103 | 96 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Rat VEGFA in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with Vegfa ELISA Kits
| Hif1a ELISA Kit | publications with Vegfa and Hif1a |
| Kdr ELISA Kit | publications with Vegfa and Kdr |
| Flt1 ELISA Kit | publications with Vegfa and Flt1 |
| Tgfb1 ELISA Kit | publications with Vegfa and Tgfb1 |
| Mmp9 ELISA Kit | publications with Vegfa and Mmp9 |
| Pgf ELISA Kit | publications with Vegfa and Pgf |
| Nrp1 ELISA Kit | publications with Vegfa and Nrp1 |
| Flt4 ELISA Kit | publications with Vegfa and Flt4 |
| Arnt ELISA Kit | publications with Vegfa and Arnt |
| Hif3a ELISA Kit | publications with Vegfa and Hif3a |
Pathways associated with Vegfa ELISA Kit
| AGE-RAGE Signaling Pathway In Diabetic Complications | AGE-RAGE Signaling Pathway In Diabetic Complications |
| Axon Guidance Pathway | Axon Guidance Pathway |
| Bladder Cancer Pathway | Bladder Cancer Pathway |
| Cytokine-cytokine Receptor Interaction Pathway | Cytokine-cytokine Receptor Interaction Pathway |
| Developmental Biology Pathway | Developmental Biology Pathway |
| EPH-Ephrin Signaling Pathway | EPH-Ephrin Signaling Pathway |
| EPHA-mediated Growth Cone Collapse Pathway | EPHA-mediated Growth Cone Collapse Pathway |
Diseases associated with Vegfa ELISA Kit
| Neovascularization, Pathologic | publications with Vegfa and Neovascularization, Pathologic |
| Retinal Diseases | publications with Vegfa and Retinal Diseases |
| Neoplasm Metastasis | publications with Vegfa and Neoplasm Metastasis |
| Diabetic Retinopathy | publications with Vegfa and Diabetic Retinopathy |
| Inflammation | publications with Vegfa and Inflammation |
| Diabetes Complications | publications with Vegfa and Diabetes Complications |
| Lung Diseases | publications with Vegfa and Lung Diseases |
| Macular Edema | publications with Vegfa and Macular Edema |
| Heart Diseases | publications with Vegfa and Heart Diseases |
| Head and Neck Neoplasms | publications with Vegfa and Head and Neck Neoplasms |
Organs/Tissues associated with Vegfa ELISA Kit
| Eye | publications with Vegfa and Eye |
| Lung | publications with Vegfa and Lung |
| Muscle | publications with Vegfa and Muscle |
| Embryonic Tissue | publications with Vegfa and Embryonic Tissue |
| Heart | publications with Vegfa and Heart |
| Liver | publications with Vegfa and Liver |
| Brain | publications with Vegfa and Brain |
| Placenta | publications with Vegfa and Placenta |
| Connective Tissue | publications with Vegfa and Connective Tissue |
| Colon | publications with Vegfa and Colon |